Loading...

Sabrina Ronen, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentRadiology
Address1700 4th St
San Francisco CA 94158
Phone415-514-4839
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    International Society of Magnetic Resonance in Medicine (ISMRM)2016Senior Fellowship Award
    World Molecular Imaging Society2015  - 2018Board of Trustees
    Academy of Radiology Research2013Distinguished Investigator
    International Society of Magnetic Resonance in Medicine (ISMRM)2008  - 2011Annual Meeting Program Committee (AMPC)
    CRUK Institute of Cancer Research1996ICR Fellowship
    Israel Ministry of Science1987Eshkol Scholarship

    Collapse Overview 
    Collapse Overview
    Sabrina M. Ronen, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Ronen completed her BS in Chemistry and Biochemistry at the Hebrew University in Jerusalem, Israel, received her MS in Chemistry from San Jose State University, and obtained her PhD in Chemical Physics from The Weizmann Institute of Science in Rehovot, Israel. She then trained as a postdoctoral fellow at the Institut Curie in Paris, France, and started her academic career at the Institute of Cancer Research in London, England.

    Dr. Ronen’s Laboratory focuses on developing and mechanistically validating robust non-invasive translatable magnetic resonance (MR)–based biomarkers that can be used to monitor oncogenic transformation and response to therapy. Dr. Ronen has ongoing research projects on monitoring PI3K signaling, detecting the mutational status of isocitrate dehydrogenase, probing the metabolism of brain tumors, and determining the metabolomic profile of pancreatic cancer.

    Expertise:
    Magnetic resonance spectroscopy (MRS), spectroscopic imaging (MRSI), imaging (MRI), metabolism, cancer, bioengineering

    Specialty:
    Preclinical cancer models

    Professional Interests:
    Magnetic resonance, spectroscopy, imaging, cancer, metabolism, cell signaling, biomarkers

    Education and Training:
    • Bachelor of Science: Hebrew University, Jerusalem, Israel - Cum Laude, Chemistry and Biochemistry
    • Masters of Science: San Jose State University, San Jose - Chemistry
    • Doctor of Philosophy: Weizmann Institute of Science, Rehovot, Israel - Chemical Physics
    • Postdoctoral Fellowship: Institut Curie, Paris, France - Imaging
    • Postdoctoral Fellowship: Harefield Hospital, London, England - Imaging


    Collapse Research 
    Collapse Research Activities and Funding
    Metabolic Imaging of Brain Tumor Response to Therapy
    NIH/NCI R01CA197254Apr 1, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Hyperpolarized arginine imaging of inflammatory cells and their inhibition in GBM
    NIH/NCI R21CA201453Dec 1, 2015 - Nov 30, 2017
    Role: Principal Investigator
    Metabolic Reprogramming in Brain Tumors
    NIH/NCI R01CA172845Feb 5, 2013 - Jan 31, 2018
    Role: Principal Investigator
    MR Imaging of IDH Mutational Status in Brain Tumors
    NIH/NCI R21CA161545Apr 2, 2012 - Mar 31, 2014
    Role: Principal Investigator
    MR Metabolic Imaging of Response to Targeted Therapies in GBM
    NIH/NCI R01CA154915Sep 8, 2011 - Jun 30, 2016
    Role: Principal Investigator
    Phosphocholine modulation by oncognenic signaling - MRS studies of mechanism
    NIH/NCI R01CA130819Sep 3, 2008 - Jul 31, 2013
    Role: Principal Investigator
    Non-invasive molecular MR spectroscopic imaging of histone deacetylase activity
    NIH/NCI R21CA120010Jun 18, 2007 - May 31, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen S, Chang SM, Nelson SJ. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017 Mar 22; 7:44792. PMID: 28327577.
      View in: PubMed
    2. Kuang R, Jahangiri A, Mascharak S, Nguyen A, Chandra A, Flanigan PM, Yagnik G, Wagner JR, De Lay M, Carrera D, Castro BA, Hayes J, Sidorov M, Garcia JL, Eriksson P, Ronen S, Phillips J, Molinaro A, Koliwad S, Aghi MK. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017 Jan 26; 2(2):e88815. PMID: 28138554.
      View in: PubMed
    3. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen S, Pieper RO. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 Nov 15; 76(22):6680-6689. PMID: 27758882.
      View in: PubMed
    4. Najac C, Ronen S. MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. Top Magn Reson Imaging. 2016 Oct; 25(5):187-196. PMID: 27748711.
      View in: PubMed
    5. Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen S. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016; 6:31397. PMID: 27507680.
      View in: PubMed
    6. Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen S. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin. 2016; 12:180-9. PMID: 27437179.
      View in: PubMed
    7. Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen S. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 7; 7(23):34942-55. PMID: 27144334.
      View in: PubMed
    8. Reed GD, von Morze C, Verkman AS, Koelsch BL, Chaumeil MM, Lustig M, Ronen S, Bok RA, Sands JM, Larson PE, Wang ZJ, Larsen JH, Kurhanewicz J, Vigneron DB, et al. Imaging Renal Urea Handling in Rats at Millimeter Resolution using Hyperpolarized Magnetic Resonance Relaxometry. Tomography. 2016 Jun; 2(2):125-135. PMID: 27570835.
      View in: PubMed
    9. Cao P, Shin PJ, Park I, Najac C, Marco-Rius I, Vigneron DB, Nelson SJ, Ronen S, Larson PE. Accelerated high-bandwidth MR spectroscopic imaging using compressed sensing. Magn Reson Med. 2016 Aug; 76(2):369-79. PMID: 27228088.
      View in: PubMed
    10. Viswanath P, Chaumeil MM, Ronen S. Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Front Oncol. 2016; 6:60. PMID: 27014635.
      View in: PubMed
    11. Radoul M, Chaumeil MM, Eriksson P, Wang AS, Phillips JJ, Ronen S. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. Mol Cancer Ther. 2016 May; 15(5):1113-22. PMID: 26883274.
      View in: PubMed
    12. Cao P, Zhang X, Park I, Najac C, Nelson SJ, Ronen S, Larson PE. (1) H-(13) C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI. Magn Reson Med. 2015 Nov 24. PMID: 26597845.
      View in: PubMed
    13. Chaumeil MM, Lupo JM, Ronen S. Magnetic Resonance (MR) Metabolic Imaging in Glioma. Brain Pathol. 2015 Nov; 25(6):769-80. PMID: 26526945.
      View in: PubMed
    14. Viswanath P, Ronen S. Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1. Mol Cell Oncol. 2016 Apr 1; 3(2):e1077922. PMID: 26985452.
      View in: PubMed
    15. Chaumeil MM, Najac C, Ronen S. Studies of Metabolism Using (13)C MRS of Hyperpolarized Probes. Methods Enzymol. 2015; 561:1-71. PMID: 26358901.
      View in: PubMed
    16. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen S. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015 Aug 1; 75(15):2999-3009. PMID: 26045167; PMCID: PMC4526330 [Available on 08/01/16].
    17. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen S. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015; 10(2):e0118781. PMID: 25706986; PMCID: PMC4338038.
    18. Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen S, Nelson SJ, Pieper RO. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 2014 Dec 1; 74(23):7115-24. PMID: 25320009; PMCID: PMC4253720 [Available on 12/01/15].
    19. Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper RO, Phillips JJ, Ronen S. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase. PLoS One. 2014; 9(9):e108289. PMID: 25243911; PMCID: PMC4171511.
    20. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen S. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. PMID: 25199993.
      View in: PubMed
    21. Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, Lupo JM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen S. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res. 2014 Aug 15; 74(16):4247-57. PMID: 24876103; PMCID: PMC4134724.
    22. Cunningham JT, Moreno MV, Lodi A, Ronen S, Ruggero D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell. 2014 May 22; 157(5):1088-103. PMID: 24855946; PMCID: PMC4140650.
    23. Lodi A, Woods SM, Ronen S. MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition. NMR Biomed. 2014 Jun; 27(6):700-8. PMID: 24706368; PMCID: PMC4154568.
    24. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen S, Weiss S, Luchman HA, Cairncross JG. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol. 2014 May; 16(5):686-95. PMID: 24366912; PMCID: PMC3984548.
    25. Ito M, Ohba S, Gaensler K, Ronen S, Mukherjee J, Pieper RO. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One. 2013; 8(5):e62351. PMID: 23667469; PMCID: PMC3646831.
    26. Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen S. HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One. 2013; 8(4):e62610. PMID: 23626839; PMCID: PMC3633900.
    27. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen S, Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 2013; 8(2):e57610. PMID: 23451252; PMCID: PMC3581484.
    28. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen S, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013 Apr 1; 19(7):1773-83. PMID: 23307858; PMCID: PMC3618605.
    29. Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen S. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun. 2013; 4:2429. PMID: 24019001; PMCID: PMC3908661.
    30. Lodi A, Woods SM, Ronen S. Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed. 2013 Mar; 26(3):299-306. PMID: 22945392; PMCID: PMC3529990.
    31. Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen S, Vigneron DB, Nelson SJ. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2013 Jul; 70(1):33-9. PMID: 22851374; PMCID: PMC3630274.
    32. Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen S. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol. 2012 Aug; 14(8):1050-61. PMID: 22670012; PMCID: PMC3408258.
    33. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen S. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):315-25. PMID: 22156546; PMCID: PMC3280799.
    34. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen S. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed. 2012 Jun; 25(6):843-51. PMID: 22134886.
      View in: PubMed
    35. Glunde K, Bhujwalla ZM, Ronen S. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011 Dec; 11(12):835-48. PMID: 22089420; PMCID: PMC4337883.
    36. Lodi A, Ronen S. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS One. 2011; 6(10):e26155. PMID: 22022547; PMCID: PMC3192145.
    37. Su JS, Woods SM, Ronen S. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed. 2012 Feb; 25(2):379-88. PMID: 22253088; PMCID: PMC3920667.
    38. Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen S. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 2012 Jan 2; 59(1):193-201. PMID: 21807103; PMCID: PMC3196046.
    39. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen S, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 2011 Jun; 33(6):1284-90. PMID: 21590996.
      View in: PubMed
    40. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen S, Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011 Jan 15; 22(2):165-78. PMID: 21119005; PMCID: PMC3020913.
    41. Brandes AH, Ward CS, Ronen S. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res. 2010; 12(5):R84. PMID: 20946630.
      View in: PubMed
    42. Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, Wang C, Zhang X, Vigneron DB, Ronen S. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res. 2010 Oct 1; 70(19):7400-10. PMID: 20858719; PMCID: PMC2948586.
    43. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen S, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun; 12(6):559-69. PMID: 20156803; PMCID: PMC2940638.
    44. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen S. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010 Feb 15; 70(4):1296-305. PMID: 20145128; PMCID: PMC2822895.
    45. Dafni H, Ronen S. Dynamic nuclear polarization in metabolic imaging of metastasis: common sense, hypersense and compressed sensing. Cancer Biomark. 2010; 7(4):189-99. PMID: 21576812.
      View in: PubMed
    46. Dafni H, Kim SJ, Bankson JA, Sankaranarayanapillai M, Ronen S. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med. 2008 Oct; 60(4):822-33. PMID: 18816866; PMCID: PMC4059608.
    47. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen S. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther. 2008 Aug; 7(8):2556-65. PMID: 18723500; PMCID: PMC2553361.
    48. Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen S. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging. 2008 Mar-Apr; 7(2):92-100. PMID: 18706291.
      View in: PubMed
    49. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen S. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther. 2006 May; 5(5):1325-34. PMID: 16731766.
      View in: PubMed
    50. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen S. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther. 2006 Jan; 5(1):187-96. PMID: 16432178.
      View in: PubMed
    51. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen S. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005 Apr 15; 65(8):3356-63. PMID: 15833869.
      View in: PubMed
    52. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen S. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst. 2003 Nov 5; 95(21):1624-33. PMID: 14600095.
      View in: PubMed
    53. Al-Saffar NM, Titley JC, Robertson D, Clarke PA, Jackson LE, Leach MO, Ronen S. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br J Cancer. 2002 Mar 18; 86(6):963-70. PMID: 11953830; PMCID: PMC2364152.
    54. Ronen S, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer. 2001 Mar 2; 84(5):691-6. PMID: 11237392; PMCID: PMC2363797.
    55. Ronen S, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res. 2001; 3(1):36-40. PMID: 11250743; PMCID: PMC150033.
    56. Smith TA, Maisey NR, Titley JC, Jackson LE, Leach MO, Ronen S. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J Nucl Med. 2000 Oct; 41(10):1753-9. PMID: 11038008.
      View in: PubMed
    57. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen S, Ross BD, Swartz HM. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia. 2000 Jan-Apr; 2(1-2):152-65. PMID: 10933074; PMCID: PMC1531871.
    58. Ronen S, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, Titley J, Cunningham DC, Griffiths JR, Leach MO, Clarke PA. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer. 1999 Jun; 80(7):1035-41. PMID: 10362112; PMCID: PMC2363054.
    59. Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, Sharp JC, Ronen S, McCready VR, Powles TJ, Smith IE. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998 Nov; 11(7):314-40. PMID: 9859939.
      View in: PubMed
    60. Ronen S, Volk A, Mispelter J. Comparative NMR study of a differentiated rat hepatoma and its dedifferentiated subclone cultured as spheroids and as implanted tumors. NMR Biomed. 1994 Sep; 7(6):278-86. PMID: 7841024.
      View in: PubMed
    61. Ronen S, Degani H. The application of 13C NMR to the characterization of phospholipid metabolism in cells. Magn Reson Med. 1992 Jun; 25(2):384-9. PMID: 1319537.
      View in: PubMed
    62. Ronen S, Rushkin E, Degani H. Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta. 1992 Mar 20; 1138(3):203-12. PMID: 1547282.
      View in: PubMed
    63. Ronen S, Rushkin E, Degani H. Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta. 1991 Oct 16; 1095(1):5-16. PMID: 1657190.
      View in: PubMed
    64. Ronen S, Stier A, Degani H. NMR studies of the lipid metabolism of T47D human breast cancer spheroids. FEBS Lett. 1990 Jun 18; 266(1-2):147-9. PMID: 2365062.
      View in: PubMed
    65. Ronen S, Degani H. Studies of the metabolism of human breast cancer spheroids by NMR. Magn Reson Med. 1989 Nov; 12(2):274-81. PMID: 2559291.
      View in: PubMed
    Sabrina's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP